Commenting on the financial results for 2002, Jörg Täubel Managing Director, stated:“It has been an excellent year for Richmond Pharmacology. The level of bookings for trials has continued to grow throughout our first year, and we have doubled our capacity for volunteers accordingly. We are delighted to announce that at the end of our first year of trading we exceeded all expectations in terms of studies completed and by showing profitability.“With good order books and detailed plans to accommodate more trials through the coming year, we are well positioned for another year of profitable growth for Richmond Pharmacology.”

Latest news

Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme

February 17, 2025
We are committed to embedding Environmental, Social, and Governance (ESG) principles into our clinical research operations to drive responsible and sustainable business growth...
Read more

Trial That Could Revolutionise Cardiac Safety Studies – Research Consortium Calls For Others To Join

February 10, 2025
The US-based Cardiac Safety Research Consortium has endorsed a project aimed at replacing the routine use of drugs...
Read more

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

April 7–11
Exploring advancements shaping the future of healthcare.
View event